SC 13G/A

$VRTX · Vertex Pharmaceuticals Incorporated

November 13, 2026 · AI-analyzed SEC filing · Verify material figures against the official SEC.gov filing

Capital Research Global Investors filed an amended Schedule 13G with the SEC regarding its holdings in Vertex Pharmaceuticals Inc. The filing, dated November 13, 2026, reports ownership as of September 30, 2026. Capital Research Global Investors, a division of Capital Research and Management Company and related investment management entities, states that it beneficially owns 17,821,661 shares of Vertex common stock, representing 7.0 percent of the approximately 253,460,924 shares believed to be outstanding.

The reporting person has sole voting power over 17,794,137 shares and sole dispositive power over 17,821,661 shares, with no shared voting or dispositive power reported. The filing is an amendment to a prior Schedule 13G and indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Get filings like this before the market reacts.

Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.

Start your free trial →